Trial Profile
A randomized, double-blind, placebo-controlled, single-centre, phase I study of saroglitazar in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- 29 Nov 2015 New trial record